Skip to content

Impact of Prophylactic Ephedrine on Fetal Heart Tracing and Uterine Tetanic Contraction After CSE

Impact of Prophylactic Ephedrine on Fetal Heart Tracing and Uterine Tetanic Contraction After Combined Spinal Epidural on Laboring Parturients

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05873218
Enrollment
100
Registered
2023-05-24
Start date
2023-06-26
Completion date
2027-05-01
Last updated
2026-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Labor

Keywords

Randomized Control Trial, Prophylactic Ephedrine, Fetal Heart Rate Tracing, Combined Spinal Epidural, Labor analgesia

Brief summary

Labor analgesia is an important component of the care of laboring patients. A known side effect of combined spinal and epidural anesthesia (a type of labor analgesia) is an increased incidence of category II fetal heart rate tracing (defined below) and low blood pressure. The study team aims to study if a prophylactic dose of ephedrine will decrease the occurrence of this type of tracing after combined spinal epidural (CSE) anesthesia placement. Ephedrine is not currently routinely used as prevention for category II tracings or low blood pressure. The use of Ephedrine in this study is investigational (this is the first time that the drug has been studied for its effect on these conditions). Fetal heart rate (FHR) tracings are classified into three categories. In clinical practice, FHR tracing categories are used as a guide to obstetric management and suggest the following approach: * Category I tracing is "reactive" and reassuring → may continue labor * Category II tracing is neither category I nor category III. For obvious reasons, category II is the broadest and largest category, consisting of various FHR tracing patterns that do not fit into either category I or category III. * Category III tracing is non-reassuring → expedited vaginal or cesarean delivery recommended. A Category II tracing is not diagnostic. Most pregnancies have at least one Category II tracing. There is not always an identifiable reason for a Category II tracing. Ephedrine is a medication that causes an increase in heart rate and blood pressure while also causing some degree of relaxation of the uterus therefore improving uterine blood flow. It has been used in the obstetric population for over 50 years without issues. The dose that the research team will administer, 7.5 mg, is below the dose the research team will often administer to treat hypotension (low blood pressure).

Interventions

DRUGEphedrine

The intervention will be up to two 7.5 mg doses of ephedrine given after the placement of a combined spinal epidural with 25 mcg intrathecal fentanyl timed 3 and 15 minutes after intrathecal opiate administration.

DRUGNormal Saline Placebo

Placebo will be administered at matching rate.

Sponsors

Icahn School of Medicine at Mount Sinai
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 55 Years
Healthy volunteers
Yes

Inclusion criteria

* Women aged 18-55 years * Requesting labor analgesia * Able to provide informed written consent * Category 1 fetal tracing prior to placement of neuraxial anesthesia

Exclusion criteria

* Refusal of neuraxial anesthesia * History of hypertension * Suspected pre-eclampsia * Category 2 or 3 fetal tracing prior to placement of neuraxial anesthesia

Design outcomes

Primary

MeasureTime frameDescription
Incidence of category II fetal heart rate tracingday 1, 30 minutes after administration of intrathecal opiateIncidence of category II fetal heart rate tracing up to 30 minutes after administration of intrathecal opiate

Secondary

MeasureTime frameDescription
Incidence of uterine tetanic contractionsday 1, 30 minutes after administration of intrathecal opiateIncidence of uterine tetanic contractions after combined spinal epidural placement
Incidence of uterine hypertorusday 1, 30 minutes after administration of intrathecal opiateIncidence of uterine hypertorus up to 30 minutes after administration of intrathecal opiate
Incidence of fetal bradycardiaday 1, 30 minutes after administration of intrathecal opiateIncidence of fetal bradycardia up to 30 minutes after administration of intrathecal opiate
Incidence of rescue administration of ephedrine, terbutaline, or nitroglycerinday 1, 30 minutes after administration of intrathecal opiateIncidence of rescue administration of ephedrine, terbutaline, or nitroglycerin up to 30 minutes after administration of intrathecal opiate
Incidence of antihypertensive treatment after ephedrine administrationday 1, 30 minutes after administration of intrathecal opiateIncidence of antihypertensive treatment after ephedrine administration
Incidence of urgent/emergent cesarean deliveryday 1, 30 minutes after administration of intrathecal opiateIncidence of urgent/emergent cesarean delivery within 30 minutes of intrathecal opiate administration
Incidence of hypotensionday 1, 30 minutes after administration of intrathecal opiateIncidence of hypotension as defined as systolic blood pressure decrease of 20% versus baseline, systolic blood pressure under 90 mmHG, or symptoms of hypotension such as light headedness
Average HR changesday 1, 30 minutes after administration of intrathecal opiateAverage HR changes 30 minutes after intrathecal opiate administration
Average blood pressure changesday 1, 30 minutes after administration of intrathecal opiateAverage blood pressure changes 30 minutes after intrathecal opiate administration of systolic and diastolic blood pressure
Number of patients with systolic blood pressure under 90 mmHGEnd of study, at 6 monthsSystolic blood pressure under 90 mmHG, or symptoms of hypotension such as light headedness

Countries

United States

Contacts

CONTACTDaniel Katz, MD
daniel.katz@mountsinai.org212-241-7475
STUDY_DIRECTORJames Leader

Icahn School of Medicine at Mount Sinai

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 7, 2026